Gene expression profiles are associated with rituximab response among people of African or Asian ancestry with systemic lupus erythematosus, but not in those of European ancestry, research suggests.
Phase 3 trial results suggest that the calcineurin inhibitor tacrolimus may represent an alternative option to cyclophosphamide for the initial treatment of lupus nephritis.
Study findings suggest that mRNA vaccines against SARS-CoV-2 have good short-term safety and immunogenicity profiles in adolescents with juvenile-onset rheumatic diseases.
Research from the COVID-19 Global Rheumatology Alliance has identified a number of factors, including diagnosis and vaccine type, that are associated with flare risk following vaccination among people with rheumatic and musculoskeletal diseases.
Hispanic and Asian people with systemic lupus erythematosus are at significantly greater risk for developing renal, hematologic, and multiorgan disease than their White counterparts, US study findings indicate.
